EDAP TMS SA Appoints Fran Schulz to Board of Directors
Ticker: EDAP · Form: 6-K · Filed: Jul 8, 2024 · CIK: 1041934
| Field | Detail |
|---|---|
| Company | Edap Tms SA (EDAP) |
| Form Type | 6-K |
| Filed Date | Jul 8, 2024 |
| Risk Level | low |
| Pages | 4 |
| Reading Time | 4 min |
| Key Dollar Amounts | $15 billion, $45B |
| Sentiment | neutral |
Sentiment: neutral
Topics: board-appointment, governance, personnel-change
Related Tickers: EDAP
TL;DR
EDAP TMS SA adds Fran Schulz to its Board of Directors.
AI Summary
EDAP TMS SA announced on July 8, 2024, the appointment of Fran Schulz to its Board of Directors. Schulz brings extensive experience to the company, which is a global leader in electromedical and electrotherapeutic apparatus.
Why It Matters
The addition of a new director with relevant experience can signal strategic growth or enhanced governance for the company.
Risk Assessment
Risk Level: low — This filing is a routine corporate announcement regarding board composition and does not involve financial performance or significant operational changes.
Key Players & Entities
- EDAP TMS SA (company) — The company making the announcement.
- Fran Schulz (person) — Newly appointed member of the Board of Directors.
- July 8, 2024 (date) — Date of the announcement and filing.
- Nasdaq: EDAP (company) — Stock ticker for EDAP TMS SA.
- KEN MOBECK (person) — Chief Financial Officer signing the report.
FAQ
Who is Fran Schulz and what is their background?
The filing states Fran Schulz has been appointed to the Board of Directors, implying relevant experience, but specific details of their background are not provided in this document.
When was Fran Schulz appointed to the Board of Directors?
Fran Schulz was appointed to the Board of Directors on July 8, 2024.
What is the ticker symbol for EDAP TMS SA?
The ticker symbol for EDAP TMS SA is EDAP on Nasdaq.
What is the primary business of EDAP TMS SA?
EDAP TMS SA is described as the global leader in electromedical and electrotherapeutic apparatus.
What type of SEC filing is this?
This is a Form 6-K report, which is a report of a foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934.
Filing Stats: 1,105 words · 4 min read · ~4 pages · Grade level 12.5 · Accepted 2024-07-08 07:15:50
Key Financial Figures
- $15 billion — ity and debt transactions, raising over $15 billion in aggregate. Ms. Schulz also has signi
- $45B — contributed to the growth of EY into a $45B firm recognized on the Fortune 100 Best
Filing Documents
- f6k_070824.htm (6-K) — 15KB
- 0001171843-24-003830.txt ( ) — 16KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: July 8, 2024 EDAP TMS S.A. /s/ KEN MOBECK KEN MOBECK CHIEF FINANCIAL OFFICER EDAP Appoints Fran Schulz to Board of Directors LYON, France, July 8, 2024 -- EDAP TMS SA (Nasdaq: EDAP) ("the Company" or "EDAP"), the global leader in robotic energy-based therapies, today announced the appointment of Fran Schulz to its Board of Directors. "We are pleased to welcome Fran Schulz to our Board of Directors," said Marc Oczachowski, Chairman of the Board of EDAP TMS. "Fran brings a wealth of executive experience in the healthcare industry, and her expertise spans across a broad array of strategic finance and accounting functions. She also possesses an in-depth understanding of U.S. and international regulatory issues, which will further strengthen our Board's leadership as we continue to expand Focal One globally." "It is exciting to join the EDAP Board at a time when the company is making such tremendous progress in changing the treatment paradigm in prostate cancer through its industry leading Focal One platform," said Fran Schulz. "I look forward to working closely with my fellow Board members and the EDAP senior management team to help advise on the company's key strategic growth initiatives, including the exciting opportunity to further expand robotic HIFU technology to treat additional diseases and conditions." Ms. Schulz is a seasoned executive with over 35 years of experience with EY who has spent her career working with large public and emerging private companies throughout the life sciences industry. She has deep experience guiding companies to execute a broad range of corporate deals including collaboration agreements, corporate spin-offs, reorganizations, and mergers and acquisitions, with personal involvement in over 100 total equity and debt transactions, ra